Hims & Hers Health (NYSE:HIMS) Releases Quarterly Earnings Results, Misses Estimates By $0.32 EPS

Hims & Hers Health (NYSE:HIMS) issued its earnings results on Monday. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32), FiscalAI reports. The company had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.

Here are the key takeaways from Hims & Hers Health’s conference call:

• Revenue and subscriber growth accelerated. Q2 revenue rose nearly 40% year over year to more than $753 million, with 300,000 net new subscribers bringing the total to nearly 3 million; management raised full-year 2026 revenue guidance to $3.1 billion–$3.3 billion.
• The company reported early benefits from its AI-native care platform, including three times more customer messaging, an approximately 50% reduction in non-clinical support tasks, and lower cancellation rates in pilot cohorts. Management expects AI investments to pay back within 12–18 months and support improved retention and cost efficiency.
• International expansion is becoming a major growth driver following the Eucalyptus acquisition. International revenue increased more than 17-fold year over year to $131 million, and the company expects international revenue of at least $600 million in 2026 while expanding U.S. specialties such as testosterone, sexual health, and dermatology overseas.
• New growth opportunities include injectable and oral testosterone before year-end and peptide-related wellness offerings, subject to regulatory developments. The company expects to launch already permitted offerings such as sermorelin, glutathione, and NAD+ by year-end, while awaiting final FDA rulemaking for additional peptides.
• Profitability and cash flow faced near-term pressure from the business mix and one-time costs. Adjusted gross margin fell to 64% as branded weight-loss products and international revenue grew, Q2 free cash flow was negative $68 million, and the company incurred approximately $81 million in acquisition, restructuring, and FTC-related legal costs; management also said international operations may remain near breakeven as it invests for scale.

Hims & Hers Health Trading Up 0.7%

Shares of NYSE HIMS traded up $0.22 during trading hours on Monday, hitting $31.81. 17,006,446 shares of the company traded hands, compared to its average volume of 26,837,846. The stock has a market capitalization of $7.36 billion, a price-to-earnings ratio of -353.44, a price-to-earnings-growth ratio of 88.90 and a beta of 2.40. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18. The company’s 50 day moving average price is $31.86 and its 200 day moving average price is $26.06. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $65.30.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Needham & Company LLC lifted their target price on Hims & Hers Health from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings downgraded Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. UBS Group set a $23.00 price objective on Hims & Hers Health in a report on Friday, May 22nd. Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Finally, Truist Financial upped their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $31.43.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Second-quarter revenue rose to $753.2 million, surpassing the $698.9 million analyst consensus. The company attributed the performance to strong subscriber growth and broader personalized healthcare offerings. Reuters article
• Positive Sentiment: Hims & Hers raised its 2026 revenue forecast to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion, above the approximately $3.0 billion consensus estimate. Wall Street Journal article
• Positive Sentiment: Third-quarter revenue guidance of $880 million-$900 million also exceeded the $845.9 million analyst estimate, reinforcing expectations for continued demand and subscriber expansion.
• Neutral Sentiment: The company said nearly 3 million people rely on its platform, while commentary surrounding the GLP-1 market remains a potential long-term growth catalyst. Company earnings release
• Negative Sentiment: Hims & Hers reported a quarterly loss of $0.37 per share, missing the $0.05 loss expected by analysts by $0.32. The earnings shortfall appears to be the primary reason the stock has moved lower despite the revenue beat and improved outlook. Benzinga article
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations or breaches of fiduciary duty related to Hims & Hers. These announcements may add headline risk and increase investor concerns, although no wrongdoing has been established. Scott+Scott investigation

Insider Buying and Selling

In related news, Director David B. Wells purchased 48,400 shares of the stock in a transaction that occurred on Tuesday, May 26th. The stock was bought at an average cost of $24.23 per share, for a total transaction of $1,172,732.00. Following the completion of the transaction, the director directly owned 224,417 shares in the company, valued at $5,437,623.91. This represents a 27.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $441,850.50. Following the transaction, the chief operating officer directly owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. This represents a 3.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 83,126 shares of company stock valued at $2,711,339 over the last 90 days. 11.76% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Binnacle Investments Inc bought a new position in Hims & Hers Health in the 3rd quarter valued at $28,000. Silicon Valley Capital Partners bought a new stake in shares of Hims & Hers Health during the third quarter worth $48,000. EverSource Wealth Advisors LLC boosted its stake in shares of Hims & Hers Health by 273.7% during the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after purchasing an additional 687 shares during the period. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health during the first quarter valued at $30,000. Finally, Greenline Wealth Management LLC bought a new position in shares of Hims & Hers Health in the fourth quarter worth about $36,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.